DE602005007604D1 - Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine - Google Patents

Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine

Info

Publication number
DE602005007604D1
DE602005007604D1 DE602005007604T DE602005007604T DE602005007604D1 DE 602005007604 D1 DE602005007604 D1 DE 602005007604D1 DE 602005007604 T DE602005007604 T DE 602005007604T DE 602005007604 T DE602005007604 T DE 602005007604T DE 602005007604 D1 DE602005007604 D1 DE 602005007604D1
Authority
DE
Germany
Prior art keywords
sulfinimines
lithiated
methylimidazole
methyl
diastereoselective addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005007604T
Other languages
English (en)
Inventor
Walter Ferdinand Filliers
Rudy Laurent Broeckx
Patrick Rene Angibaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE602005007604D1 publication Critical patent/DE602005007604D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
DE602005007604T 2004-05-03 2005-04-28 Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine Active DE602005007604D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076320 2004-05-03
PCT/EP2005/051928 WO2005105782A1 (en) 2004-05-03 2005-04-28 Diastereoselective addition of lithiated n-methylimidazole on sulfinimines

Publications (1)

Publication Number Publication Date
DE602005007604D1 true DE602005007604D1 (de) 2008-07-31

Family

ID=34968457

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005007604T Active DE602005007604D1 (de) 2004-05-03 2005-04-28 Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine

Country Status (11)

Country Link
US (1) US7524961B2 (de)
EP (1) EP1758885B1 (de)
JP (1) JP4917021B2 (de)
CN (1) CN100567290C (de)
AT (1) ATE398612T1 (de)
AU (1) AU2005238221B2 (de)
CA (1) CA2563805C (de)
DE (1) DE602005007604D1 (de)
ES (1) ES2308500T3 (de)
HK (1) HK1101326A1 (de)
WO (1) WO2005105782A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005021878D1 (de) * 2004-05-03 2010-07-29 Janssen Pharmaceutica Nv Diastereoselektives syntheseverfahren mit 6-brom-4-(3-chlorphenyl)-2-methoxychinolin
ATE398612T1 (de) * 2004-05-03 2008-07-15 Janssen Pharmaceutica Nv Diastereoselektive addition von lithiiertem n- methylimidazol an sulfinimine
CN108371711A (zh) 2015-08-17 2018-08-07 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症患者的方法
SG11201903786UA (en) 2016-11-03 2019-05-30 Kura Oncology Inc Farnesyltransferase inhibitors for use in methods of treating cancer
JP2021526513A (ja) * 2018-05-18 2021-10-07 クラ オンコロジー， インコーポレイテッド ティピファニブの合成

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL123568A (en) * 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
US6566385B2 (en) * 2000-01-12 2003-05-20 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001051126A1 (en) * 2000-01-12 2001-07-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
WO2002020015A1 (en) * 2000-09-05 2002-03-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
MXPA03008205A (es) * 2001-03-12 2004-01-29 Janssen Pharmaceutica Nv Procedimiento para la preparacion de compuestos de imidazol.
WO2002079147A2 (en) * 2001-03-30 2002-10-10 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2004037816A1 (en) * 2002-10-28 2004-05-06 Chugai Seiyaku Kabushiki Kaisha Benzofuran compounds having antitumor activity
TW200504057A (en) * 2003-02-27 2005-02-01 Chugai Pharmaceutical Co Ltd Benzothiophene derivative
ATE398612T1 (de) * 2004-05-03 2008-07-15 Janssen Pharmaceutica Nv Diastereoselektive addition von lithiiertem n- methylimidazol an sulfinimine

Also Published As

Publication number Publication date
US20070293679A1 (en) 2007-12-20
JP2007536333A (ja) 2007-12-13
ATE398612T1 (de) 2008-07-15
AU2005238221B2 (en) 2010-09-30
AU2005238221A1 (en) 2005-11-10
CN1946709A (zh) 2007-04-11
HK1101326A1 (en) 2007-10-12
JP4917021B2 (ja) 2012-04-18
CN100567290C (zh) 2009-12-09
US7524961B2 (en) 2009-04-28
EP1758885A1 (de) 2007-03-07
ES2308500T3 (es) 2008-12-01
CA2563805C (en) 2012-11-13
CA2563805A1 (en) 2005-11-10
WO2005105782A1 (en) 2005-11-10
EP1758885B1 (de) 2008-06-18

Similar Documents

Publication Publication Date Title
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
BRPI0516905A (pt) processo para a preparação de um derivado n-[2-(2-piridinil)etil]carboxamida e compostos
EA200500146A1 (ru) Моноэтансульфонат 3-z-[1-4-(n-((4-метилпиперазин-1-ил)метилкарбонил)-n-метиламино)анилино)-1-фенилметилен]-6-метоксикарбонил-2-индолинона и его применение в составе фармацевтической композиции
ATE440833T1 (de) Antithrombotische diamide
EA201000300A1 (ru) Способ синтеза соединений, пригодных для лечения гепатита с
CY1108455T1 (el) Νεος στεροειδης αγωνιστης δια fxr
SG166019A1 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
EA200400606A1 (ru) ИНГИБИТОРЫ ФАКТОРА Ха И ДРУГИХ СЕРИНОВЫХ ПРОТЕАЗ, ВОВЛЕЧЁННЫХ В КОАГУЛЯЦИОННЫЙ КАСКАД
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
RS52099B (en) SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS
WO2005115398A3 (en) Hiv integrase inhibitors
MY141224A (en) Crystalline form of a biphenyl compound
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
DE602005007604D1 (de) Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
RS50574B (sr) (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline
RS51226B (sr) Derivati azapeptida kao inhibitori hiv proteaze
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
DE502004008871D1 (de) Antiandrogene pyrrolidine mit tumorhemmender wirksamkeit
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων

Legal Events

Date Code Title Description
8364 No opposition during term of opposition